; or (II) may be employed by the Office during the 6-year period beginning on the date on which the registered lobbyist terminates its registration in accordance with section 4(d) of the Lobbying Disclosure Act of 1995 ( 2 U.S.C. 1603(d) ) or the agent terminates its status, as applicable. (ii) Senior executives of law-breaking companies No former senior executive of a covered entity (as defined in clause (iii)) who was employed by such entity on any date on which wrongful conduct is the subject of a settlement, decree or enforcement action described in clause (iii)(III) occurred— (I) may be appointed to the position of Director of the Office; or (II) may be employed by the Office during the 6-year period beginning on the later of— (aa) the date of the settlement; and (bb) the date on which the enforcement action has concluded. (iii) Covered entity The term covered entity means any entity that is currently— (I) a drug manufacturer; (II) a wholesaler; and (III) (aa) operating under Federal settlement, including a Federal consent decree; or (bb) the subject of an enforcement action in a court of the United States or by an agency. (4) Duties (A) In general The Office shall— (i) prepare and submit applications for approval to the Food and Drug Administration, or enter into contracts for such submission, for the manufacture of applicable drugs when authorized under this section, and in accordance with subparagraph (G); (ii) acquire rights to manufacture applicable drugs as authorized under this section; (iii) manufacture, or enter into contracts with entities, with preference for nonprofit entities and public partners, to manufacture, applicable drugs as authorized under this section; (iv) determine a fair price for each applicable drug, in accordance with subparagraph (B); (v) sell manufactured applicable drugs at a fair price as authorized under this section